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The concept hat drugs that relax vascular smooth muscle 
could have a favorable lkct on the clinical syndrome of 
heart failure grew out of acute hemodynamic observations. 
The 6rst systematic studies (l-3) of vasodWors in the 
setting of left ventrkular dysfunction were carried out in the 
early 1970s with infusion of phentohunine or sodium nitro- 
prusside (1). These early studies demonstrated that vasodi- 
lator drugs could profoundly improve the performance ofthe 
left ventricle. During i&sion of nitroprusside, the elevated 
leftventricuhullllingpressurewasreduced,thelowcardiac 
output was strikgly increased and the arkrial pressure 
decreased only modestly with little or no increase in heart 
rate. A similar esponse could be demonstrated with other 
vasodWor drugs, but a diiering proMe of efkct appeared to
berelatedtotherelariveactionofthese~onthevenopls 
andarkrialvasadature.Itwasthusassumedthatdrugsthat 
alteredvenouscapacitancetoallowpoolingofbloodinthe 
periphery would have a more prominent ekt on cardiac 
6llingpressure,anddrugsthat&xedarkrialtoneandthus 
reduced&edancetoleftventricuhu@ztionwouldhavea 
morepr&undekctoncardiacoutputandstrohevolume 
(4). These observations led to the now well established 
prkiple that the hiI@ left ventricle is sensitive to imped- 
ance (5) and that progressive left ventricuhu dysfunction is
inpartamanifestationofheightenedvasculartonecontrib 
uting to.both impedance and preload -on, which 
might lead to progressive systolic dysftmck and ventticu- 
lar dilation (6). 
Ikanshuinq these acute hemodynamic e&cts ofvasodi- 
lator drugs into long-term e&acy of vasodihktor therapy 
required not only the development oforally ekctive vaw 
dilatortegimens,butalsoaleapoffaiththathm&iate 
improvement i  left ventricular pe&mance could result in 
long-term relief of symptoms. This concept could be tested 
onlybyutilizingdrugswith&ctivevascuhuactionsand 
monitorin clinical responses in the syndrome of heart 
failure. Initial studies were performed using various nitrate 
preparations (7,8) and potent arkrial dWor!r, in&ding 
hydrakine (9,lO) and minoxidil (II). The devetapmen of
vasalWordrugsworl@throughditkentvascuhumech- 
anisms led to the study ofalpha-adrenergic blocking agents 
(12,13), converting enzyme inhibitors (M-16), calcium cbab 
nel antagonists (17,18) and newer agents uch as kequbmn 
(19,20). All of these drugs produce afavorable e&t on left 
ventricular perfommmx, but the overall hemodynamic re-
spoll!XtotheSeagentscannotnecessarilybe~by 
thesimplemechanisticmodeljustde&bed.Thisv&bility 
of lw3ponse has stimulated exploratbm of neurohormonal 
reflexcontrolme&anismsaspossiblecomrMomtothe 
overallhemodynamice&ctofthesedtugs.Thus,caWertng 
enzymeinhMorsappearonacnteadmWWbmtoprcduce 
agreaterdecreaseinbloodpressureandalesserkreasein 
cardiacoutputthaaoccurwith~,andllose- 
quinanappearstoproduceagreater ilErea%hlheartrate 
thandoanyoftheotherdrugs(19). Whetheranydthese 
elk!ctsarerelatedtoditectairdiacactionsofthesedrW 
rather than peripheral vascuhu and neurohormonal efkts 
remains unclear. 
clinical~ofv~ 
Thesearchfbrclinicaleillcacyaf vssodilatordrugsinthe 
syndrome of heart fbilure has generaUy involved oubb- 
blind hials last& 16 months, with assessment af SYmptoms 
andexercktolerance~the~oreadpoints.~tilieips 
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these criteria, tbe ealcacy cf uimes, the combinBtion f 
bydralazine aad i808crbide dinitrate, converth18 enzyme 
inhiiitor~, ilosequinau and vasosekctive calcium atage 
nists ha3 been demonstrated 111 adequately coutrclled trids. 
Thesestudies~susgestthatagentscapableofmain- 
taining a lower vascular tone can favorably aEect the syn- 
dromeofchlDnichealtfaihue. 
Themaj@udeofthebenellcialelktofvasodikordnqgs 
and their comparative ellkcy in improving the syndrome of 
heartfailurehavebeelldiaIculttoquantitate.Increasesin 
ex~timeandoxygenconsumption whe 6asexNis 
measlued have usually been quite modest (Fig. I) (21). In 
general, the improvement in exercise capacity appears to
occurovertimeandtoreachitspeakbetween3and6 
monthsafterrandomMon.lkanslatio~~oftheimprovement 
ofpe&exerckecap&ytoreliefofsymptomsor~fed 
quality dliie is parkMy dikult to validate. Attempts to 
monitor quality of lik as an end point fin thempeutk trials 
have requhed the development of suitable hWruments that 
canassessthedisabilitythatmostpatientswlthheartfailure 
exhibit (22). Because peak exercise capacity may not be a 
suitable suKo8ate for the submaximal work loads that most 
patients perform in their daily lives, attempts have been 
made to quantitate forms of submaximal exerck These 
eiktshavenotyetproducedaprotocolthatcanreliablybe 
applied to assess drug elkacy in heart failure (23). 
Usin a diseapespecilic i&rument developed at the 
UllkSityOfMi~wehavemadeinitialattemptsto 
~chagesinpeakexercisecapacitytochangesin 
~dkbilityinpatklltswlthherutfaiblE(22).TheSe 
~~studieshavesuggestedthatpeakexercisecapacityand 
quality of life changes may be nownt in heart failure, 
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butthatbothmaymeasureausefule~pointforafavorable 
ekct oftherapy. Indeed, inour preliminary studies (24). an 
increase in peak oxygen consumption of >2 min usually was 
assockted with an improved quality of life score (Fig. 2). 
Exercise improvements of a more modest degree were 
associated with a variable r sponse in a sekdministered 
questionnak Because exercise t sting isexpensive, time 
consumi~ and prone to technical mblems, avalidated and 
reliable questionnaire that could more directly assess the 
overall capacity of the patient to perform daily activities 
mi@ matly f&Nate drug development for his syndrome. 
Efk!tN on Mortality 
Becent emphasis in clinical trhds has been placed on 
attempts to prolong life in patients with heart failure. Short- 
enedliFkexpectancyisaprominentfindingoncethediagno- 
sisofheartlWrehasbeenmade.IUostdeathsinpatients 
witb documented heart faibue are from cardiivascular 
apses. Although acute myocardhd infArction may be a 
tennkl event in patients with wronary artery disease 
umlerlyi~the heart failure, the dority of deaths inthis 
syndrome occur suddenly in the absence ofnew symptoms 
orfromprogressivepumpfaihuzinpatientswithincreasing 
symptoms re ponding poorly to therapy (25). It is assumed 
that hese two mechanisms of death are independent, wi h 
tbeformer4atedtoaventrkulararrhythmiaandthehUer 
to progressive hnpairment of systolic fimction of the left 
ventricle. The mechanistic dyslktion may, however, be 
dilllculttomonitor.Theeventsleadinguptodeatharenot 
alwayseasytodocumentandevenwithcarefUll 
the clinical story may be misleading. For example, some 
appase tly sudden deaths inpatients with heart fsilure have 
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represent electromechanical d ssociation (26). There is also a 
clear elation between left ventricular dysfunction a d ven- 
tricular arrhythmias so that a documented electrical event 
might still represent the syndrome of progressive h art 
failure (27). 
A favorable e&t of drug therapy on survival in heart 
faihue would require that he drug prevent lethal ventricuhu 
arrhythmias or have along-term be&i&l elfect on ventric- 
ular dysfunction r other compensatory mechanisms that 
may indepemkntly contribute opump failure or sudden 
death. The hope for vasodilator d ugs was that by altering 
loading conditions on the left ventticle, the ventricle would 
be allowed to improve its emptying and improve its end- 
diastolic size so that a favorable Ion&term effect on remod- 
eling might reduce the risk of pump failure and favorably 
iniluence the risk of sudden death. This pamdigm requires 
the assumption that he vasoconstricted an neurohormon- 
ally activated state of heart failure contributes directly to 
mssion of the syndrome orto the incidence ofsudden 
death. 
Vasodikors were the first agents to be subjected to a 
long-term tr% to assess mortality effects. In the ilrst 
Vasodikor-Heart Failure Trial (V-HeFI’ I) (28), patients 
with left ventricular dysfunction aud exercise intolerance 
treated with digoxin and a diuretic agent were randomly 
assigned to receive prazosin, the combination of hydmiazine 
and isosorbide initrate orplacebo ina multicenter Veterans 
Affairs Cooperative Study. In that rial (28), the hydrahuine- 
isosorbide diitrate combination produced a signiticantly 
lower cumulative mortality rate than did placebo. This 
favorable eBect on mortal&y was most prominent at between 
2 and 3 years after andomization. In that study (28). a 
reduction f both sudden death and mortality due to progres- 
sive pump fake was observed. In contrast tothe favorable 
e!Ikct of hydralazine-isosorbii dinitrate, prazosin therapy 
was associated with no reduction i mortahty and no evi- 
dence of clinical benelit. The failure of the alpha- 
adtenoceptor blocker prazosin to favorably Muence the 
course of heart failure despite the evidence that its vasodi- 
latoreffectper!&edhlthistrialsuggeststhatthevasodii 
mechanism itself is not adequate oaccount for a long-term 
ikaable ettkct of therapy. 
Mechdsms of Favorable litif& 
An at&active hypothesis is that he long-term benefit of 
some vasodiMor drugs may be related to their antiproliier- 
ative rather than to their vasodWor eiIects (29). Compen- 
satory responses to left ventricular dysfunction i  heart 
faihue include changes in the struchue ofvascular smooth 
muscle and increases in myocardial mass and ventricular 
chamber volume. If these stnmtuml changes have a long- 
term deleterious e&c& agents hat could inhibit theii occur- 
rence might favorably aikct long-term outcome. Nitrates 
exert heir vascular smooth muscle Ikcts through genera- 
tion of nitric oxide, which is also the putative endothelium- 
derived relaxing factor that plays an important roIe in the 
maintenance ofr&ced arteriolar tone (30). Nit& OX& ti 
mly produces vasodilation but also inhibits platelet aggra 
gation and inhibits vascular smooth muscle and my& 
@Wtll. Thus, hg-term elllcacy of a vasodW~ ’ 
that inch&s oral nitrates might exert at least -7h: 
favorable hemodynamic etkct through inhibition of tissue 
growth. Although alpha,+ubcnoceptom have been imph- 
cated in neonatal myocyte growth in vitro (31), alpha,- 
admnoceptor blockade has not been demonstmted o be 
elktive in preventing ventricular hypermphy iu intact 
animals. The etlicacy of other non-angiotensin-convert& 
enzyme inhibitor vasodilator d ugs, such as hydmkne, 
minoxidil, f osequinan d the calcium antagonists, on vas- 
cular smooth muscle and myocardial growth as not been 
adequately studied. 
A comparison between enalapriJ and the hydralake- 
isosorbide iitrate combination was carried out in V-HeFI’ 
II. In this trial, a patient cohort similar to that studied in 
V-HeFT I was randomly assigned to receive ither enalapril 
(10 mg) twice daily or hydrakine (300 mg) and isombide 
din&ate (120 I@ My (32). During long-termfollow-up, the 
hydralazine-isosorbide dinitrate combination produced a 
greater improvement in peak exercise oxygen consumption 
and left ventricular ejection fraction than did enalaptil. 
Nonetheless, the 2-year mortality rate was signiicantly 
lower in the enaiapril-treated patients and the overall mor- 
tality rate after amaximum of 5 years offollow4tp study also 
strongly favored enalapril. These observations have further 
emphasized that vasodiiator drugs and angiotensin- 
converting enzyme inhibitors do not necessarily act hrough 
the same mechanism in producing their favorable e&c& in 
heart failure. Indeed, in V-HeFI’ II, enalapd therapy was 
associated with a siqni6cantly lower plasma norepkphrine 
level compated with that associated with hydrakine and 
isosorbidedinitratethempyduringthelstyearafterrandom- 
ization (33). with less fmquent emergence of ventricular 
tachycardiion serialHohermonitoring(W)andalowerrish 
of sudden death (25). These observations of an apparent 
dikingpxufdeofactionsofthesetwothempeuticre&nens 
raise the possibility hat vasodilakw drugs and converting 
ettzymeinhtGtorsmightbeusedtogetherasamoreeffecti~ 
form of therapy. This hypothesis is currently being tested in 
V-HeFI’ III, ia which a vasosdective cdcim am is 
being utilized to suppkunent theangiotensin~V~ en- 
zyme inhibitor enalaptil inan attempt tolessen morbidity 
and mortality inthe syndrome (35). 
The complexities of the heart failure syndtokle arc nm 
becommgmoreapparent.LeftventricuhuejectioafractioR 
and exercise intolemnce are WY correlated but both 
contribute independently to prognosis. Nwrohormonal aC- 
tjV&D CBMDt be predicted from the sedty d Left Ven- 
t&hr dysfunakm or the severity of symptom% but this 
neurohorm~activation~ywaethelesswmributetothe 
mssion of the diise and shorten lik expectancy. 
Ventricular rhythmias are certainly correlated with the 
swerityaMtventrkbdysbctbn,buttheirindepen- 
dentroleinsuddendeathandthee&acyoftheirsuppres- 
!&ionremainhighlycon~.Beethmaybetheonly 
deibiteendpointforpharmawl&ce&acy,butthemulti- 
pleme&aknsofdeathraisethep0s8ibilitythatW 
~=Y~~~m~bytberapYm~ 
morethmonemechdsm. 
ThetriabinheartfkiluretheMbresuggestthatwsin& 
endpdntcan&sfac&lydescribetheelEcwydadrug. 
Multipleobservationscarriedout overaprolongedperiodd 
timemaylJenecessalytode6neretionaltherapyth3tcanbe 
recommended for routine use. Attempts oidentifj subsets 
of patients with this multietiologic aad multkchanistic 
syndrome are entinly approppiate. Furthermore, thempeu- 
tictrialswithvasudilatorsorotherintewentionsaimedat 
earlytRatmentbefbrethedevelopmentofadvancedleft 
. 
ventncb dysfimctioa are potentially the most e&&e 
waytoplx&undlyalterthemorbidityalld~yillthis 
syndrome. 
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